Philippines - English - FDA (Food And Drug Administration)

pan-ject pharmaceuticals corporation; distributor: pan-ject pharmaceuticals corporation - tramadol hydrochloride - solution for injection (i.m/i.v.) - 50mg/ml (100mg/2ml)

Philippines - English - FDA (Food And Drug Administration)

pan-ject pharmaceuticals corporation; distributor: pan-ject pharmaceuticals corporation - dexamethasone (as sodium phosphate) - solution for injection - 4mg/ ml

Philippines - English - FDA (Food And Drug Administration)

pan-ject pharmaceuticals corporation; distributor: pan-ject pharmaceuticals corporation - phenytoin (as sodium) - solution for injection - 50mg/ml (250mg/5ml)

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - pantoprazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - pantoprazole sodium sesquihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - pantoprazole sodium sesquihydrate -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 20mg